Secondary Hyperaldosteronism Documentation Best Practices
Customize your policy alerts
Sign up for all wellsense_health_plan policy alerts
Know when wellsense_health_plan releases new policies or updates existing guidance.
Monitor payer policy activity
Guidance for clinicians on documenting secondary hyperaldosteronism (ICD-10: E26.1) to ensure accurate diagnosis capture and linkage to the primary causal condition for WellSense Health Plan members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Documentation criteria for accurate diagnosis capture
Covered when ALL of the following documentation elements are present in the medical record:
These are documentation best-practice criteria to ensure accurate diagnosis capture.
The source document lists common primary causes of secondary hyperaldosteronism without specifying exclusions. Typical etiologies identified include obstructive renal artery disease, renal vasoconstriction (for example with accelerated hypertension), and edematous disorders such as heart failure, cirrhosis with ascites, and nephrotic syndrome. There are no explicit exclusions noted for these causes in the guidance; the focus is on recognizing and documenting the primary condition when capturing a diagnosis of secondary hyperaldosteronism.
The document does not contain any explicit statements labeling situations or services as not medically necessary. Instead, it provides documentation requirements and best-practice guidance to ensure accurate diagnosis capture, emphasizing elements clinicians should include (clinical findings, identification of the primary condition, explicit linking language, and assessment/plan for both conditions).
Coding
| E26.1 | Secondary hyperaldosteronism |
| I50.22 | Chronic systolic congestive heart failure |
| K74.60 | Unspecified cirrhosis of liver |
Provider Actions & Documentation
Code secondary hyperaldosteronism with the primary diagnosis
Document E26.1 (Secondary hyperaldosteronism) in the medical record alongside the primary diagnosis code (for example, I50.22 for chronic systolic congestive heart failure or K74.60 for cirrhosis) to show linkage between the secondary condition and its underlying cause.
Document diuretic adjustments and MR antagonist plans
Include treatment actions in the plan such as diuretic adjustment (e.g., increasing furosemide) and consideration or initiation of a mineralocorticoid receptor antagonist (e.g., spironolactone) when documenting management for secondary hyperaldosteronism due to heart failure or cirrhosis.
- Example: Furosemide increased to 40 mg daily (heart failure scenario).
- Example: Add spironolactone 25 mg once daily (cirrhosis scenario).
- Document referrals when planning MR antagonist initiation (e.g., cardiology, GI).
Document clinical findings and explicit linkage to primary cause
Record the clinical findings that supported the diagnosis (e.g., blood pressure, presence and severity of edema/ascites, and any abnormal labs), identify the primary condition responsible for aldosteronism and its status, and use explicit linking language (e.g., 'due to', 'secondary to', 'caused by', 'associated with').
- Include an assessment and plan for both the primary and secondary conditions.
- Use explicit linking phrasing to tie E26.1 to the primary diagnosis in the note.
Risk of denial or improper diagnosis capture without documented findings/linkage
If the clinical findings that led to the diagnosis (such as BP, edema, or abnormal labs) or an explicit linkage to the primary condition are not documented, the diagnosis capture may be improper and could lead to administrative issues or denial risk.
- Failure to identify the primary condition and its status or to use linking language risks incomplete documentation capture.
Background
Secondary hyperaldosteronism is increased adrenal production of aldosterone driven by non‑adrenal stimuli and is most often caused by decreased renal blood flow or other systemic conditions. Common mechanisms include reduced renal perfusion from obstructive renal artery disease or renovascular vasoconstriction (such as in accelerated hypertension), and physiologic responses to volume‑overload edematous disorders like heart failure, cirrhosis with ascites, and nephrotic syndrome. Laboratory patterns and the degree of renin and aldosterone elevation can vary by cause, but clinical documentation should focus on the precipitating primary condition and objective findings (for example blood pressure, edema, and relevant abnormal labs) to support the diagnosis.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.